Scholar Rock Holding Corp (SRRK): R&D Expense
$208.44M
Year ended 2025-12-31
$207.41M
Trailing 12 months to 2026-06-30
+18.8%
3-year compound annual growth
+23.0%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $208.44M | +12.9% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $184.55M | +51.4% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $121.90M | -2.0% | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | $124.44M | +14.7% | 2024-03-19, From 2022-01-01 |
| 2021-12-31 | $108.47M | +46.5% | 2023-03-07, From 2021-01-01 |
| 2020-12-31 | $74.06M | +36.6% | 2022-03-07, From 2020-01-01 |
| 2019-12-31 | $54.22M | +49.3% | 2021-03-09, From 2019-01-01 |
| 2018-12-31 | $36.31M | +82.1% | 2020-03-12, From 2018-01-01 |
| 2017-12-31 | $19.94M | n/a | 2019-03-19, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $208.44M | +12.9% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Amgen Inc (AMGN) | 2025-12-31 | $7.27B | +21.9% |
| Repligen Corp (RGEN) | 2025-12-31 | $54.18M | +25.4% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $9.08M | +33.1% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $94.77M | -4.8% |
| Biogen Inc. (BIIB) | 2025-12-31 | $1.78B | -10.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $17.73M | +42.2% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $5.80B | -1.8% |
Compare SRRK, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗